In this webinar, Lais Berro, PhD presents recent research demonstrating the anxiolytic, sedative and abuse-related effects of benzodiazepine drugs, and how they correlate with telemetry-based EEG recordings in a translational non-human primate model.

Benzodiazepines are known to induce electroencephalography (EEG) changes in rodents and humans that are associated with distinct behavioral effects and have been proposed as quantitative biomarkers for GABAA receptor modulation. Specifically, central EEG beta and occipital EEG delta activity have been associated with anxiolysis and sedation, respectively. The extent to which nonhuman primates show the same dose- and topography-dependent effects remained unknown. Critically, rhesus macaques have been shown recently to share GABAA receptor subtype distributions in the brain that, unlike rodent species, align with human findings.

Lais Berro, PhD recently demonstrated that the benzodiazepine alprazolam induces dose- and topography-dependent EEG spectral power changes in rhesus monkeys. In this webinar, Dr. Berro reviews the main behavioral models used in her laboratory to investigate the anxiolytic, sedative and abuse-related effects of benzodiazepine drugs. She correlates her findings with recent data obtained using telemetry-based EEG recording, with the goal of promoting EEG evaluation in nonhuman primates as a valuable and translational model for studying benzodiazepine pharmacology.

Key Topics Include:

  • Gain a conceptual understanding of benzodiazepine pharmacology and GABAA receptor modulation
  • Become familiar with the main models used to investigate the behavioral effects of benzodiazepines in nonhuman primates
  • Learn the dose- and topography-dependent EEG spectral power changes induced by benzodiazepine drugs across species
  • Describe how benzodiazepine-induced EEG changes correlate with the different behavioral effects of these drugs

Presenters

Instructor
Psychiatry and Human Behavior
University of Mississippi Medical Center

Dr. Lais F. Berro has a Ph.D. Degree from Universidade Federal de São, Brazil. She completed her postdoctoral studies at the University of Mississippi Medical Center, where she is currently an Instructor. Her long term research interests involve the investigation of the mechanisms underlying the relationship between sleep and drug abuse.

Production Partner

Data Sciences International

Data Sciences International (DSI) is the leader in preclinical physiological monitoring offering telemetry, instrumentation, software and services to help advance science. Industries served include: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, Medical Devices, Government, and Biotechnology.

Harvard Bioscience, Inc.

Harvard Bioscience is a global leader in the manufacturing and distribution of solutions to advance life science research. For over 110 years, we have served the changing needs of life scientists in over 100 countries. Our expanding portfolio of brands include instruments for organ and animal research, cell analysis, molecular biology, fluidics, and laboratory consumables.

Additional Content From Data Sciences International

Additional Content From Harvard Bioscience, Inc.

Related Content